Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
 

Share

    


In This Section

Home / Blurbs

Blurbs

FDA Approves Rucaparib for Recurrent Ovarian, Fallopian Tube, Peritoneal Cancer

On April 6, 2018, the Food and Drug Administration approved rucaparib (Rubraca, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Read the FDA announcement here.